secwatch.observer — SEC 8-K summary
======================================

Issuer:     Wave Life Sciences Ltd. (WVE)
CIK:        0001631574
Form:       8-K
Filed at:   2025-03-26T23:59:59+00:00
Accession:  0001193125-25-063184
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Wave reports positive Phase 2 FORWARD-53 data for WVE-N531 in DMD; plans NDA in 2026
--------------------------------------------------------------------------------

- TTR improved 3.8 seconds vs natural history (p<0.05); fibrosis reduced 28.6% (p<0.01); CK declined 50%.
- Mean dystrophin 7.8% (88% >5%); muscle health reversal shown; no SAEs.
- FDA confirms accelerated approval pathway; NDA filing planned in 2026 based on all FORWARD-53 data.
- Monthly dosing supported by 61-day half-life; additional DMD exons (52,51,45,44) CTAs expected in 2026 addressing ~$2.4B US market.
- Pipeline milestones: WVE-006 AATD data, WVE-007 obesity data H2 2025, WVE-003 HD IND H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1631574/000119312525063184/0001193125-25-063184-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1631574/000119312525063184/d918658d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-063184

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer